Request Your Free eBook Now:

"Moving Cell & Gene Therapies Forward"

Reach a higher level of structural variant detection and genome integrity assessment.

Optical genome mapping detects all classes of structural variants for applications in cell and gene therapy.

Cell and gene therapies are constantly at risk of acquiring mutations. It is crucial to keep the safety of these therapies at the forefront of our considerations. Serial passaging and prolonged cell culture growth can lead to genomic abnormalities over time. Additionally, genetic editing often inadvertently leads to genomic structural variants, which can render treatments pathogenic. Establishing the safety of CGT is crucial to therapeutic success, and regulatory agencies uphold stringent standards to ensure patient safety. Unfortunately, many current methods of genomic characterization fall short of reliably detecting these changes.

In this Flipbook you will learn how to take a step forward in the latest advancements in cell and gene therapy quality control and genomic integrity assessment.

• Overview of current challenges in genome integrity assessment for cell & gene therapies: An in-depth look at the limitations of current methods, including karyotyping, PCR, CMA, and NGS, and how they fall short in reliably detecting structural variants and genomic abnormalities.
   
• An innovative approach to genomic integrity assessment: Learn how OGM revolutionizes the assessment of genome integrity and screening for off-target events in cell and gene therapies.
   
• Real-world utilization and testimonials: Insights from professionals in the field, including pathologists and scientists, sharing their experiences with optical genome mapping and real-world evidence of the technology's impact on research and therapeutic development.

Get the Flipbook now.

Offered Free by: Bionano
See All Resources from: Bionano